CG Oncology (NASDAQ:CGON) Given New $117.00 Price Target at Morgan Stanley

CG Oncology (NASDAQ:CGON – Get Free Report) had its price target increased by stock analysts at Morgan Stanley from $102.00 to $117.00 in a research note issued on Wednesday, Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Morgan Stanley‘s target price points to a potential upside of 47.90% from the stock’s current price.

Other equities research analysts also recently issued research reports about the company. Truist Financial restated a “buy” rating and set a $100.00 target price (up from $85.00) on shares of CG Oncology in a research report on Tuesday. Royal Bank Of Canada lowered CG Oncology from an “outperform” rating to a “sector perform” rating and upped their price target for the company from $80.00 to $97.00 in a research note on Tuesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of CG Oncology in a report on Thursday, October 15th. Guggenheim lowered their price objective on CG Oncology from $90.00 to $89.00 and set a “buy” rating for the company in a research report on Monday, November 9th. Finally, HC Wainwright lifted their price objective on CG Oncology from $100.00 to $115.00 and gave the stock a “buy” rating in a research report on Tuesday. Eight analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, CG Oncology has an average rating of “Moderate Buy” and a consensus price target of $98.78.

View Our Latest Report on CGON

CG Oncology Stock Up 0.2%

CGON stock traded up $0.17 during trading on Wednesday, hitting $79.11. The company had a trading volume of 112,946 shares, compared to its average volume of 1,148,053. The firm has a 50-day moving average price of $68.35 and a 200-day moving average price of $66.82. CG Oncology has a 12 month low of $37.01 and a 12 month high of $93.95. The stock has a market cap of $7.07 billion, a price-to-earnings ratio of -28.59 and a beta of 0.35.

CG Oncology (NASDAQ:CGON – Get Free Report) last announced its quarterly earnings data on Friday, November 6th. The company reported ($0.64) EPS for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.19. The firm had revenue of $1.60 million for the quarter, compared to analyst estimates of $0.55 million. CG Oncology had a negative return on equity of 24.58% and a negative net margin of 3,851.09%. Equities analysts expect that CG Oncology will post -2.97 EPS for the current year.

Insiders Place Their Bets

In related news, Director Leonard E. Post sold 1,000 shares of the stock in a transaction that occurred on Monday, November 16th. The shares were sold at an average price of $92.00, for a total value of $92,000.00. Following the transaction, the director directly owned 1,000 shares in the company, valued at $92,000. This represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders have sold 3,000 shares of company stock valued at $227,040 in the last quarter. Corporate insiders own 4.80% of the company’s stock.

Institutional Trading of CG Oncology

Several institutional investors and hedge funds have recently made changes to their positions in CGON. Virtu Financial LLC acquired a new position in shares of CG Oncology in the 3rd quarter valued at $295,000. Aquatic Capital Management LLC boosted its position in shares of CG Oncology by 111.2% in the 3rd quarter. Aquatic Capital Management LLC now owns 24,435 shares of the company’s stock worth $1,732,000 after purchasing an additional 12,867 shares during the last quarter. Goldman Sachs Group Inc. boosted its position in shares of CG Oncology by 32.5% in the 3rd quarter. Goldman Sachs Group Inc. now owns 1,136,464 shares of the company’s stock worth $80,564,000 after purchasing an additional 278,751 shares during the last quarter. Toronto Dominion Bank increased its holdings in CG Oncology by 177.7% in the third quarter. Toronto Dominion Bank now owns 798,676 shares of the company’s stock valued at $56,618,000 after purchasing an additional 511,044 shares during the last quarter. Finally, Jump Financial LLC bought a new stake in CG Oncology in the third quarter valued at about $4,665,000. Institutional investors own 26.56% of the company’s stock.

Key Headlines Impacting CG Oncology

These are some of the CGON headlines that stood out recently:

  • Positive Sentiment: The PIVOT-006 Phase 3 trial reported a 68% reduction in bladder-cancer recurrence risk, strengthening the outlook for cretostimogene and driving investor interest. Reuters trial coverage
  • Positive Sentiment: Analysts raised targets after the trial news: HC Wainwright lifted its target to $115 and Truist to $100, both maintaining Buy ratings; Wedbush raised its target to $91 and kept Outperform. The higher targets signal increased optimism about the results’ potential. HC Wainwright ratings
  • Negative Sentiment: Director Leonard Post sold 1,000 shares for $92,000, cutting his direct stake by half. The transaction could weigh modestly on sentiment, though it is small relative to the company’s overall value. SEC ownership filing

CG Oncology Company Profile

(Get Free Report)

CG Oncology is a clinical-stage biotechnology company focused on developing treatments for bladder cancer. Based in Irvine, California, the company’s research centers on therapies delivered directly into the bladder. Its lead investigational therapy, cretostimogene grenadenorepvec (formerly CG0070), is an oncolytic immunotherapy being developed for non-muscle-invasive bladder cancer, including disease that has not responded to Bacillus Calmette-Guérin (BCG) treatment. The modified virus is designed to target cancer cells and stimulate an immune response.

Featured Stories

Analyst Recommendations for CG Oncology (NASDAQ:CGON)

Receive News & Ratings for CG Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CG Oncology and related companies with MarketBeat.com's FREE daily email newsletter.